Formulary guidance and transparency from P&T to point of care


Reality Check on Type 2 Diabetes

Market access for type 2 diabetes treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Almost half of the lives under the commercial and health exchange formularies have utilization management restrictions  
  • Class Trends: Health insurers are targeting diabetes via prevention programs and technology 
  • Key Findings: This is a heavily contracted class, in which costs are high but so are rebates 

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.